Sanofi Reports 3Q18 Orthobiologic Revenue of €72MM, -24.2% vs. 3Q17

Sanofi’s Synvisc and Synvisc-One products, injections that replace hyaluronic acid in knee joints affected by osteoarthritis, continued their challenging year by posting 3Q18 revenue of $88.7MM, a year-over-year decline of 24.2%. Sales in the U.S., by far the largest market for Synvisc products, were especially hard hit, posting a 30.1%...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us